The story of Sildenafil offers a intricate case study for analysts eyeing pharma. While first sales were remarkable, present patent expiry and the arrival of cheaper versions have severely impacted earnings. In https://poppieefpt288666.loginblogin.com/49186965/the-blue-pill-and-the-pharmaceutical-industry-a-risky-investment